PharmaView   DEC.2006

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Creative Design: Case study of Taxotere Visuals

                         

FDA Approves Velcade (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma

Millennium Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of VELCADE for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Dec 08, 2006

King Pharmaceuticals reported today that the U.S. Food and Drug Administration ("FDA") has approved the Company's revised prescribing information for its Skelaxin(R) (metaxalone) product. Skelaxin(R) is a leading branded muscle relaxant,

Dec 04, 2006

Merck Announces Janumet, the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes

Merck & Co., Inc. today announced the trademark Janumet for MK-0431A, the Company's investigational oral medicine combining sitagliptin phosphate with metformin for type 2 diabetes.

Dec 01, 2006

Direct to Consumer: Don't Wait

When a pharmaceutical product faces tough positioning challenges, sometimes the answer is to focus not just on the messages sent to doctors and patients, but on the messages doctors and patients communicate to each other.

Dec 01, 2006

Alternative Media: Health on Demand

As broadband-internet connections and digital-cable services become household mainstays, on-demand video is becoming a viable tool for consumers seeking medical information. Forward-looking pharma companies are discovering that by harnessing this new technology, they can provide custom-tailored media direct to consumers.

Dec 01, 2006

Cutting Through e-lclutter

When it comes to digital communication, pharma has been slow out of the blocks. But while drug companies may rue their fast-diminishing ability to control brand messages online, they have a golden opportunity to engage in rich two-way dialogue.

Dec, 2006

Pfizer's Warning Signs

At an all-day meeting at a Times Square hotel last Saturday, Pfizer gathered 100 top cardiologists and showed them data for the company's panoply of heart drugs. The star: torcetrapib, Pfizer's experimental pill to raise good cholesterol, touted as one of the most important medicines in a generation. The doctors were enthralled.

Dec 08, 2006

Sanofi sees FDA response on Acomplia by April 26

Sanofi-Aventis expects to get a decision from U.S. regulators by April 26 on whether it may sell anti-obesity pill and potential blockbuster Acomplia in the world's largest drug market, following a six-month review.

Dec 08, 2006

Lilly sees slower profit growth in 2007

Eli Lilly and Co. said on Thursday it is on track to meet its 2006 growth forecast of 8 percent to 12 percent, but projected slower profit growth in 2007 though its revenues will grow at a faster pace next year.

Dec 07, 2006

Forest drug tops Lilly's in depression trial

Forest Laboratories Inc.'s Lexapro proved more effective than Eli Lilly and Co.'s newer antidepressant Cymbalta in treating moderate to severe depression in a small head-to-head study of the two medicines, Forest said on Wednesday.

Dec 06, 2006

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!